Edwards Lifesciences downgraded to Sell from Neutral at UBS UBS downgraded Edwards Lifesciences due to the slower than expected U.S. Sapien launch and European deceleration. Price target lowered to $80 from $95.
News For EW From The Last 14 Days
Check below for free stories on EW the last two weeks.
Edwards Lifesciences upgraded to Outperform from Market Perform at Wells Fargo Wells Fargo upgraded Edwards Lifesciences citing a number of positive developments since it downgraded the stock in December 2013, including strong Q4 Sapien results outside the U.S. and the company's successful first-inman transcatheter mitral valve implants. Wells raised its price target range for shares to $82-$83 from $67-$69.